2 news items
Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
SYRE
15 May 24
laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
SYRE
9 May 24
Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking
- Prev
- 1
- Next